Published 09/26/2024 11:00:33 p.m.

FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug, Cobenfy, the first new treatment for the disorder in over seven decades.
Doctors can start prescribing Cobenfy by late October, as stated by Adam Lenkowsky of Bristol Myers Squibb.
The wholesale cost for Cobenfy will be $1,850 per month, although insurance coverage may lower this for many patients.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

Reuters

US FDA approves Bristol Myers' schizophrenia drug

The U.S. FDA approved Bristol Myers Squibb's schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects, the health regulator said.

09/26/2024 11:00:33 p.m.·United Kingdom

Read Full Article

abc News

FDA approves first new schizophrenia drug in more than 30 years – englishtimes.uk

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, made by Bristol Myers Squibb, combines two medications, xanomeline and trospium chloride, and is taken in pill form twice a day. In clinical trials, this combination helped manage symptoms such as hallucinations, delusions, and disorganized thinking, common in schizophrenia. “Schizophrenia is one …

09/27/2024 12:38:15 a.m.·United States

Read Full Article

CNBC

FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades

The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with schizophrenia.

09/26/2024 10:46:55 p.m.·United States

Read Full Article

The Hill

FDA approves new type of schizophrenia drug

The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to schizophrenia treatment in decades,” said Tiffany Farchione, the director of the Division of Psychiatry, Office of Neuroscience in the FDA’s Center for Drug…

09/27/2024 1:52:00 p.m.·Washington, United States

Read Full Article

Benzinga

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades - Bristol-Myers Squibb (NYSE:BMY)

On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the treatment via Karuna Therapeutics deal for $330 per share in cash for a total equity value of $14 billion. Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selecti…

09/27/2024 11:56:17 a.m.·New York, United States

Read Full Article

Newsweek

FDA approves new schizophrenia drug in 70-year first

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

09/27/2024 1:17:55 p.m.·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left10Leaning Right5Center15Last Updated09/28/2024 7:56:35 a.m.Bias Distribution

50% Center

Bias Distribution

50% of the sources are Center

50% Center

+10

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades

0 Articles

0 Articles

US FDA approves Bristol Myers' schizophrenia drug

US FDA approves Bristol Myers' schizophrenia drug

FDA approves first new schizophrenia drug in more than 30 years – englishtimes.uk

FDA approves first new schizophrenia drug in more than 30 years – englishtimes.uk

FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades

FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades

FDA approves new type of schizophrenia drug

FDA approves new type of schizophrenia drug

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades - Bristol-Myers Squibb (NYSE:BMY)

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades - Bristol-Myers Squibb (NYSE:BMY)

FDA approves new schizophrenia drug in 70-year first

FDA approves new schizophrenia drug in 70-year first

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics